Formycon AG
XETRA:FYB
Formycon AG
XETRA:FYB
Price:
44.3 EUR
-1.23%
Updated:
May 8, 2024
Section:
Relative Value
The Relative Value of one
FYB
stock under the Base Case scenario is
60.5
EUR.
Compared to the current market price of 44.3 EUR,
Formycon AG
is
Undervalued by 27%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
FYB
Relative Value
Base Case
60.5
EUR
Undervaluation 27%
Valuation Multiples
Multiples Across Competitors
FYB Competitors Multiples
Formycon AG Competitors
Formycon AG Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| DE |
|
Formycon AG
XETRA:FYB
|
720m EUR | 9.3 | 9.5 | 461.6 | -1 899.1 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
287.1B USD | 5.3 | 59.6 | 12.9 | 19.7 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
161.1B USD | 5.5 | 42.8 | 18.2 | 30 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
106.9B USD | 8.2 | 27.7 | 22.4 | 24.8 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
105.7B USD | 10.7 | 29.2 | 23.4 | 24.5 | |
| AU |
|
CSL Ltd
ASX:CSL
|
135.1B AUD | 6.3 | 36 | 21.8 | 27 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
81.6B USD | 3 | 168.5 | 6.8 | 8.9 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
46.4B USD | 9 | -7.8 | -8.4 | -7.5 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
31.9B USD | 3.3 | 27.3 | 14 | 17.5 | |
| KR |
|
Celltrion Inc
KRX:068270
|
40.1T KRW | 18.4 | 74.9 | 45.8 | 63.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
